Zimmer Holdings, Inc. 8-K Summary
Business Context and Reporting Period
Zimmer Holdings, Inc. filed this Form 8-K on July 25, 2013, to report its results of operations for the quarter ended June 30, 2013. The filing incorporates by reference the earnings release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references an attached press release (Exhibit 99.1) containing these figures but does not reproduce them within the body of this 8-K document.
Material Changes and Non-GAAP Measures
The company utilizes two types of non-GAAP financial measures to evaluate performance:
- Constant Currency Sales: Sales translated at predetermined exchange rates to exclude the effect of foreign currency fluctuations.
- Adjusted Operating Performance: Adjusted net earnings and diluted EPS that exclude specific items, including:
- Inventory step-up and other inventory/manufacturing charges.
- Provisions for Durom Acetabular Component product claims.
- Special items such as acquisition and integration costs, asset impairment charges from prior acquisitions, employee termination benefits, consulting fees, litigation matters, and costs related to global restructuring initiatives.
Management states these measures provide a clearer view of ongoing operating trends and are used in incentive compensation programs. All non-GAAP measures are reconciled to GAAP measures in the attached press release.
Guidance, Outlook, and Risks
The filing mentions that the attached earnings release includes projected adjusted diluted EPS, but the specific guidance figures are not present in this text. The document highlights the Durom Acetabular Component product claims as a specific contingency affecting reported earnings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures for the quarter ended June 30, 2013.
- Verify the reconciliation between reported GAAP earnings and the adjusted non-GAAP earnings.
- Assess the magnitude of the Durom Acetabular Component product claim provisions and restructuring charges.
- Confirm the projected adjusted diluted EPS guidance provided in the press release.